The Cyclin-dependent Kinase-like 5 Deficiency Disorder market growth is driven by factors like increase in the prevalence of Cyclin-dependent Kinase-like 5 Deficiency Disorder, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Cyclin-dependent Kinase-like 5 Deficiency Disorder market report also offers comprehensive insights into the Cyclin-dependent Kinase-like 5 Deficiency Disorder market size, share, Cyclin-dependent Kinase-like 5 Deficiency Disorder epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Cyclin-dependent Kinase-like 5 Deficiency Disorder market size growth forward.
Some of the key highlights from the Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Insights Report:
- Several key pharmaceutical companies, including UCB S.A., Ultragenyx Pharmaceutical, Amicus Therapeutics, Ovid Therapeutics, REGENXBIO, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.
- The total Cyclin-dependent Kinase-like 5 Deficiency Disorder market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major market.
- As per DelveInsight analysis, the Cyclin-dependent Kinase-like 5 Deficiency Disorder market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Landscape
Cyclin-dependent Kinase-like 5 Deficiency Disorder Overview
CDKL5 deficiency disorder is a rare developmental encephalopathy (DE) caused by pathogenic variants in the gene cyclin-dependent kinase-like 5 (CDKL5). It is a rare X-linked genetic disorder first identified in 2004. The most common symptoms include early-onset, difficult to control seizures and neurodevelopmental impairment that affects cognitive, motor, speech and visual function.
The CDKL5 gene is responsible for creating a protein necessary for normal brain development and function. Pathogenic variants in the CDKL5 gene reduce the amount of functional CDKL5 protein or alter its activity in neurons. A shortage (deficiency) of CDKL5 or impairment of its function disrupts brain development. The exact cause of CDKL5 deficiency disorder is not known and most pathogenic variants within the CDKL5 gene occur spontaneously and are not passed down through families.
CDKL5 genetic changes or mutations are found in children diagnosed with many other neurologic disorders, including infantile spasms, Lennox-Gastaut Syndrome, Rett Syndrome, West Syndrome, and autism. The diagnosis is initially suspected based on history, symptoms, and physical examination. Moreover, it is confirmed by the molecular genetic testing that can usually be performed by either a blood or saliva sample that is sent to a laboratory for genetic sequencing. Seizures in CDKL5 deficiency disorder are difficult to treat and often require multiple anti-seizure medications.
Further, in many cases, the physical symptoms of CDKL5 can be alleviated and managed with Physiotherapy/physical therapy, occupational therapy, and speech and augmentative communication therapy. Recently in March 2022, the US Food and Developmental Administration (FDA) approved Ztalmy (ganaxolone) to treat seizures associated with CDKL5 deficiency disorder in patients 2 years of age and older. This is the first treatment for seizures associated with CDD and the first treatment specifically for CDKL5 deficiency disorder.
Do you know the treatment paradigms for different countries? Download our Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Sample Report
Cyclin-dependent Kinase-like 5 Deficiency Disorder Epidemiology Segmentation
DelveInsight’s Cyclin-dependent Kinase-like 5 Deficiency Disorder market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Cyclin-dependent Kinase-like 5 Deficiency Disorder historical patient pools and forecasted Cyclin-dependent Kinase-like 5 Deficiency Disorder patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Cyclin-dependent Kinase-like 5 Deficiency Disorder Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Cyclin-dependent Kinase-like 5 Deficiency Disorder Prevalence
- Age-Specific Cyclin-dependent Kinase-like 5 Deficiency Disorder Prevalence
- Gender-Specific Cyclin-dependent Kinase-like 5 Deficiency Disorder Prevalence
- Diagnosed and Treatable Cases of Cyclin-dependent Kinase-like 5 Deficiency Disorder
Visit for more @ Cyclin-dependent Kinase-like 5 Deficiency Disorder Epidemiological Insights
Cyclin-dependent Kinase-like 5 Deficiency Disorder Treatment Market
The Cyclin-dependent Kinase-like 5 Deficiency Disorder market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cyclin-dependent Kinase-like 5 Deficiency Disorder market trends by analyzing the impact of current Cyclin-dependent Kinase-like 5 Deficiency Disorder therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Cyclin-dependent Kinase-like 5 Deficiency Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cyclin-dependent Kinase-like 5 Deficiency Disorder market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Cyclin-dependent Kinase-like 5 Deficiency Disorder market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Cyclin-dependent Kinase-like 5 Deficiency Disorder Emerging Therapies and Key Companies:
- Fenfluramine: UCB S.A.
CDKL5 Deficiency Disorder Emerging Drugs
Fenfluramine: UCB S.A.
Fenfluramine is an investigational serotonin releasing agent that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of CDKL5 Deficiency Disorder.
For more information, visit Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Cyclin-dependent Kinase-like 5 Deficiency Disorder, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Cyclin-dependent Kinase-like 5 Deficiency Disorder epidemiology in the 7MM
- Cyclin-dependent Kinase-like 5 Deficiency Disorder marketed and emerging therapies
- Cyclin-dependent Kinase-like 5 Deficiency Disorder companies
- Cyclin-dependent Kinase-like 5 Deficiency Disorder market drivers and barriers
Key Questions Answered in the Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Report 2032:
- What was the Cyclin-dependent Kinase-like 5 Deficiency Disorder market share distribution in 2019, and how would it appear in 2032?
- What is the total Cyclin-dependent Kinase-like 5 Deficiency Disorder market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Cyclin-dependent Kinase-like 5 Deficiency Disorder market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Cyclin-dependent Kinase-like 5 Deficiency Disorder market projected to expand at 7MM?
Table of Contents:
1 Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Key Comprehensive Insights
2 Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Report Introduction
3 Competitive Intelligence Analysis for Cyclin-dependent Kinase-like 5 Deficiency Disorder
4 Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Analysis Overview at a Glance
5 Executive Summary of Cyclin-dependent Kinase-like 5 Deficiency Disorder
6 Cyclin-dependent Kinase-like 5 Deficiency Disorder Epidemiology and Market Methodology
7 Cyclin-dependent Kinase-like 5 Deficiency Disorder Epidemiology and Patient Population
8 Cyclin-dependent Kinase-like 5 Deficiency Disorder Patient Journey
9 Cyclin-dependent Kinase-like 5 Deficiency Disorder Treatment Algorithm, Cyclin-dependent Kinase-like 5 Deficiency Disorder Current Treatment, and Medical Practices
10 Key Endpoints in Cyclin-dependent Kinase-like 5 Deficiency Disorder Clinical Trials
11 Cyclin-dependent Kinase-like 5 Deficiency Disorder Marketed Therapies
12 Cyclin-dependent Kinase-like 5 Deficiency Disorder Emerging Therapies
13 Cyclin-dependent Kinase-like 5 Deficiency Disorder: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Cyclin-dependent Kinase-like 5 Deficiency Disorder
16 Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Key Opinion Leaders Reviews
18 Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Drivers
19 Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Cyclin-dependent Kinase-like 5 Deficiency Disorder Epidemiology 2032
DelveInsight’s “Cyclin-dependent Kinase-like 5 Deficiency Disorder – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Cyclin-dependent Kinase-like 5 Deficiency Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline 2023
“Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cyclin-dependent Kinase-like 5 Deficiency Disorder market. A detailed picture of the Cyclin-dependent Kinase-like 5 Deficiency Disorder pipeline landscape is provided, which includes the disease overview and Cyclin-dependent Kinase-like 5 Deficiency Disorder treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/